Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo; Richard S. Finn; Shukui Qin; Kwang–Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari David Baron; Joong‐Won Park; Guohong Han; Jacek Jassem; Jean Frédéric Blanc; Arndt Vogel; Д. В. Комов; T.R. Jeffry Evans; Carlos López; Corina E. Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann‐Lii Cheng

doi:10.1016/s0140-6736(18)30207-1

Related publications

Article2021

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, В. В. Бредер

Article2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean–Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset,

Article2018

Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Riccardo Lencioni, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Fabio Piscaglia, Guohong Han, Masafumi Ikeda, Krzysztof Simon, Д. В. Комов, Xuenong Ouyang, T.R. Jeffry Evans, Max W. Sung, Terri A. Binder, Andrew Damon, Silvija Kraljevic, Min Ren, Baek‐Yeol Ryoo

Article2017

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean–Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo

Article2014

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Richard S. Finn, Ann‐Lii Cheng, Kenji Ikeda, Masatoshi Kudo, Toshiyuki Tamai, Corina E. Dutcus, Steven Younger, Kwang–Hyub Han, Shukui Qin, Éric Raymond